These agents had previously been tested preclinically to redirect T-cell killing against conventional tumor cell lines in culture and humanized immunodeficient mice co-engrafted with human tumor cell lines and CD34+ hematopoietic precursors 5, 11, 12. This evidence concerns the gene CD34 and neoplasm.